Resources
Learn more about gaps in meningococcal vaccine coverage and the importance of vaccinating your eligible older adolescent patients against all 5 leading meningococcal serogroups1-3*

*ACIP recommends routine administration of a MenACWY vaccine for all healthy persons aged 11 to 18 years, with a single dose at age 11 or 12, followed by a booster dose at age 16. ACIP also recommends a 2-dose MenB vaccine series administered 1 to 6 months apart for healthy persons aged 16 to 23 years on the basis of shared clinical decision-making, with a preferred age range of 16 to 18. For further guidance on individuals in older age groups or at increased risk, see ACIP Meningococcal Vaccine Recommendations.3

ACIP=Advisory Committee on Immunization Practices; HCP=healthcare professional; Ipsos=Institut Public de Sondage d'Opinion Secteur; NIS=National Immunization Survey.

References

  1. Pingali C, Yankey D, Elam-Evans LD, et al. Vaccination coverage among adolescents aged 13–17 years—National Immunization Survey–Teen, United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(34):912-919.

  2. Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019;134:103571.

  3. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1-41.